Related Experiment Video
Updated: Oct 22, 2025
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
17.1K
Is Post-Transplant Cyclophosphamide the New Methotrexate?
Alberto Mussetti1,2, Annalisa Paviglianiti1,2, Rocio Parody1,2
1Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, 08908 Barcelona, Spain.
Journal of Clinical Medicine
|August 27, 2021
Summary
Post-transplant cyclophosphamide (PT-Cy) is a key advance in haploidentical donor allogeneic hematopoietic cell transplantation (alloHCT), reducing GVHD. Its role in HLA-identical settings is under investigation.
Area of Science:
- Hematology
- Immunology
- Transplantation Science
Background:
- Post-transplant cyclophosphamide (PT-Cy) has revolutionized haploidentical donor allogeneic hematopoietic cell transplantation (alloHCT).
- Its efficacy in preventing graft-versus-host disease (GVHD) has led to widespread adoption globally.
- PT-Cy's success challenges traditional GVHD prophylaxis in HLA-identical settings.
Purpose of the Study:
- To review the outcomes of PT-Cy-based GVHD prophylaxis in haploidentical alloHCT.
- To summarize current evidence for PT-Cy in HLA-identical alloHCT.
- To discuss future directions for PT-Cy in alloHCT.
Main Methods:
- Review of existing clinical trial data and literature.
- Analysis of outcomes in haploidentical and HLA-identical transplantation settings.
- Synthesis of evidence regarding GVHD prophylaxis strategies.
Main Results:
- PT-Cy demonstrates significant efficacy in reducing GVHD in haploidentical alloHCT.
- Evidence is emerging regarding the potential role and outcomes of PT-Cy in HLA-identical settings.
- Ongoing trials aim to clarify the optimal use of PT-Cy across different donor types.
Conclusions:
- PT-Cy represents a major advancement in alloHCT, particularly for haploidentical transplants.
- Further research is needed to establish the definitive role of PT-Cy in HLA-identical donor transplantation.
- PT-Cy offers a simplified and effective approach to GVHD prophylaxis.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
01:29Therapeutic Drug Monitoring: Affecting Factors
32
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
32
01:22Bone Marrow Sampling and Transplants
583
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
583
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
246
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
246